<div id="readability-page-1"><div><p><span>Feb 02 (Reuters) - IDEXX Q4 EBIT margin 28.9%.</span></p><ul><li><span>Q4 revenue USD 1,091 million vs. IBES estimate USD 1,073 million</span></li><li><span>Q4 gross margin 60.3%</span></li><li><span>outlook FY EPS USD 14.29-14.8</span></li><li><span>outlook FY revenue USD 4,632-4,720 million</span></li></ul></div></div>

<p>Feb 02 (Reuters) - IDEXX Q4 EBIT margin 28.9%.Q4 revenue USD 1,091 million vs. IBES estimate USD 1,073 millionQ4 gross margin 60.3%outlook FY EPS USD 14.29-14.8outlook FY revenue USD 4,632-4,720 million</p>

Reuters

Ark Genomic Revolution ETF

iShares Biotechnology ETF

SPDR S&P Health Equip

Mesa Laboratories

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

IDEANOMICS INC

iShares US Healthcare Providers

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares US Medical Devices

IDEXX Labs

VanEck Biotech ETF

iShares Genomics Immunology and Healthcare ETF

BRIEF-IDEXX Q4 EPS USD 3.08